PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Progastrine Et Cancers S.à R.l.

USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, active 2021–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).

Explore the portfolio See the ranking
6
Total patents granted
4
CPC technology areas
13.8
Avg claims per patent
-
5-year filing velocity

The verdict

Progastrine holds 6 US patents across 4 technology areas, rank #42,457 of 50,000 tracked assignees.

#42,457
of 50,000 US assignees by volume
Top 31%
by Innovation Score (42.1/100)
13.8
avg claims per patent

Portfolio overview

Progastrine Et Cancers S.à R.l. has been granted 6 US utility patents between 2021 and 2024, placing Progastrine Et Cancers S.à R.l. at rank #42,457 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 13.8 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, Progastrine Et Cancers S.à R.l. is one of the more focused assignees in the PatentsView dataset. By volume, Progastrine sits between Processchamp, Llc (6 patents, rank #42,453) and Propack Processing And Packaging Systems, Inc. (6 patents, rank #42,461) - the closest US assignees by grant volume. The composite Innovation Score of 42.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2021 through 2024, with 6 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Progastrine Et Cancers S.à R.l.'s 13.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Progastrine Et Cancers S.à R.l. against peers pursuing similar technology classes.

Who files at Progastrine's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Progastrine holds 6 patents at rank #42,457, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Progastrine

By rank, the assignees closest to #42,457 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Progastrine's primary technology class.

Progastrine's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

42 Top 31% higher than 69% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 202120232024 1
USPTO utility patent grants by year · 2021–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table
Progastrine Et Cancers S.à R.l. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2021 1 16.7%
2023 4 66.7%
2024 1 16.7%

Which technologies does Progastrine Et Cancers S.à R.l. patent most?

Top 4 of 4 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard

Where it ranks

Overall rank by patents

#42,457

Across all tracked assignees

Innovation Score

42.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Progastrine Et Cancers S.à R.l. hold?
Progastrine Et Cancers S.à R.l. holds 6 US granted patents filed between 2021 and 2024, spanning 4 technology areas.
What is Progastrine Et Cancers S.à R.l.'s Innovation Score?
Progastrine Et Cancers S.à R.l. has an Innovation Score of 42.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Progastrine Et Cancers S.à R.l. focus on?
Progastrine Et Cancers S.à R.l.'s top technology area is C07K (PEPTIDES) with 6 patents. The company has filed patents in 4 CPC subclasses total.
Is Progastrine Et Cancers S.à R.l.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Progastrine Et Cancers S.à R.l..
What does claim depth mean for Progastrine Et Cancers S.à R.l.'s patents?
Progastrine Et Cancers S.à R.l.'s patents average 13.8 claims each. This falls within the standard range, providing solid legal coverage.
How is the Progastrine Et Cancers S.à R.l. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Progastrine's 6 grants land it in the top 31% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Progastrine ranks #42,457 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C07K - see who else leads that technology area. C07K leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.